QIAGEN acquires Parse Biosciences Inc for US$225m

QIAGEN NV is paying US$225m upfront for the acquisition of Parse BioSciences. Additionally Parse Biosciences’ equityholders are eligible for additional milestone payments of up to $55m. The acquisition strengthens QIAGEN’s position in the rapidly growing single-cell analysis market, projected to grow from US$1.2bn in 2024 to US$2.1bn by 2029, a roughly 10% annual growth rate.

Parse is expected to contribute US$40m to QIAGEN’s 2026 revenue, with accretive impact from 2028. Thierry Bernard, Chief Executive Officer (CEO) and Managing Director of QIAGEN N.V, called the deal a “critical step toward data-driven biology.”This expansion is being driven by AI-based drug discovery as pharmaceutical and biotechnology companies generate large-scale cellular datasets to train predictive models of biology.

Platform-independent technology

Parse Biosciences is distinctly positioned to capitalise on this trend with Evercode, a proprietary combinatorial barcoding platform. The company’s Evercode platform uses combinatorial barcoding, enabling researchers to analyse millions to billions of cells, critical for AI-powered drug discovery. Complementary tools include Trailmaker software and GigaLab, capable of processing 2.5 billion cells annually. The integration enhances QDI bioinformatics, enabling end-to-end workflows from sample preparation to AI-based large-scale data interpretation.

The acquisition positions QIAGEN in a high-value AI-driven segment, essential for cellular disease research and targeted drug development. Parse serves 3,000+ labs in 40+ countries, including top research institutions and major pharmaceutical companies.